Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long‐term extension studies over 7 years

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We characterized tofacitinib efficacy/safety in Indian vs rest of the world (ROW; excluding India) RA patients. METHODS: Efficacy data were pooled for disease‐modified antirheumatic drug (DMARD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chopra, Arvind, Shobha, Vineeta, Chandrashekara, Srikantiah, Veeravalli, Sarath C. M., Sharma, Reena, Rao, Uppuluri R., Pandya, Sapan, Wagh, Shrikant, Kadel, Jugal K., Thorat, Amit V., Adhav, Charles, Santos Estrella, Paul, Yu, Wei, Kwok, Kenneth, Wouters, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496174/
https://www.ncbi.nlm.nih.gov/pubmed/32478474
http://dx.doi.org/10.1111/1756-185X.13853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496174/
https://www.ncbi.nlm.nih.gov/pubmed/32478474
http://dx.doi.org/10.1111/1756-185X.13853

Ejemplares similares